Literature DB >> 23848282

Generation and characterization of adeno-associated virus producer cell lines for research and preclinical vector production.

John Martin1, Amy Frederick, Yuxia Luo, Robert Jackson, Michelle Joubert, Bruce Sol, Francis Poulin, Eric Pastor, Donna Armentano, Samuel Wadsworth, Karen Vincent.   

Abstract

Adeno-associated virus (AAV) producer cell lines represent an effective method for large-scale production of AAV vectors. We set out to evaluate and characterize the use of an abbreviated protocol to generate "masterwells" (MWs; a nonclonal cell population) as a platform for research and preclinical vector production. In this system, a single plasmid containing three components, the vector sequence, the AAV rep, and cap genes, and a selectable marker gene is stably transfected into HeLaS3 cells. Producer cell lines generating an AAV2 vector expressing a secreted form of human placental alkaline phosphatase (SEAP) have been created. Several MWs showed vector yields in the 5×10(4) to 2×10(5) DNase-resistant particles/cell range, and the productivity was stable over >60 population doublings. Integrated plasmid copy number in three high-producing MWs ranged from approximately 12 to 50; copies were arranged in a head-to-tail configuration. Upon infection with adenovirus, rep/cap copy number was amplified approximately 100-fold and high yield appeared to be dependent on the extent of amplification. Rep/cap gene expression and vector packaging both reached a peak at 48 hr postinfection. AAV2-SEAP vector was produced in 1-liter shaker culture and purified for assessment of vector quality and potency. The data showed that the majority of the capsids from the MWs contained vector DNA (≥70%) and that purified vector was free of replication-competent AAV. In vitro and in vivo analyses demonstrated that potency of the producer cell-derived vector was comparable to vector generated via the standard transfection method.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23848282     DOI: 10.1089/hgtb.2013.046

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  23 in total

1.  OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy.

Authors:  Mario Mietzsch; Sabrina Grasse; Catherine Zurawski; Stefan Weger; Antonette Bennett; Mavis Agbandje-McKenna; Nicholas Muzyczka; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther       Date:  2014-01-23       Impact factor: 5.695

2.  OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA.

Authors:  Mario Mietzsch; Vincent Casteleyn; Stefan Weger; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther       Date:  2015-08-06       Impact factor: 5.695

3.  OneBac 2.0: Sf9 Cell Lines for Production of AAV1, AAV2, and AAV8 Vectors with Minimal Encapsidation of Foreign DNA.

Authors:  Mario Mietzsch; Henrik Hering; Eva-Maria Hammer; Mavis Agbandje-McKenna; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther Methods       Date:  2017-02       Impact factor: 2.396

4.  Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy.

Authors:  Stifani Satkunanathan; Jun Wheeler; Robin Thorpe; Yuan Zhao
Journal:  Hum Gene Ther       Date:  2014-09-11       Impact factor: 5.695

5.  High-Density Recombinant Adeno-Associated Viral Particles are Competent Vectors for In Vivo Transduction.

Authors:  Qizhao Wang; Jenni Firrman; Zhongren Wu; Katie A Pokiniewski; C Alexander Valencia; Hairong Wang; Hongying Wei; Zhenjing Zhuang; LinShu Liu; Stephanie L Wunder; Mario P S Chin; Ruian Xu; Yong Diao; Biao Dong; Weidong Xiao
Journal:  Hum Gene Ther       Date:  2016-08-22       Impact factor: 5.695

6.  Characteristics of Minimally Oversized Adeno-Associated Virus Vectors Encoding Human Factor VIII Generated Using Producer Cell Lines and Triple Transfection.

Authors:  Bindu Nambiar; Cathleen Cornell Sookdeo; Patricia Berthelette; Robert Jackson; Susan Piraino; Brenda Burnham; Shelley Nass; David Souza; Catherine R O'Riordan; Karen A Vincent; Seng H Cheng; Donna Armentano; Sirkka Kyostio-Moore
Journal:  Hum Gene Ther Methods       Date:  2017-02       Impact factor: 2.396

7.  In Vivo Potency Testing of Subretinal rAAV5.hCNGB1 Gene Therapy in the Cngb1 Knockout Mouse Model of Retinitis Pigmentosa.

Authors:  Johanna E Wagner; Lena Zobel; Maximilian J Gerhardt; Catherine R O'Riordan; Amy Frederick; Simon M Petersen-Jones; Martin Biel; Stylianos Michalakis
Journal:  Hum Gene Ther       Date:  2021-09-20       Impact factor: 4.793

8.  Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.

Authors:  Yu-Shan Tseng; Kim Van Vliet; Lavanya Rao; Robert McKenna; Barry J Byrne; Aravind Asokan; Mavis Agbandje-McKenna
Journal:  J Virol Methods       Date:  2016-07-14       Impact factor: 2.014

9.  Detailed Protocol for the Novel and Scalable Viral Vector Upstream Process for AAV Gene Therapy Manufacturing.

Authors:  Nagarathinam Selvaraj; Chao-Kuei Wang; Brian Bowser; Trevor Broadt; Samir Shaban; Jenna Burns; Nirmala Saptharishi; Peter Pechan; Diane Golebiowski; Asaf Alimardanov; Nora Yang; George Mitra; Ramarao Vepachedu
Journal:  Hum Gene Ther       Date:  2021-03-30       Impact factor: 4.793

Review 10.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.